| Citation: |
LIU Tiantian, BI Jingwang, WANG Jun. Relationship Between EGFR Mutation and Brain Metastasis in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2017, 44(3): 189-192. DOI: 10.3971/j.issn.1000-8578.2017.03.007
|
To investigate the relationship between epidermal growth factor receptor (EGFR) mutation and brain metastasis in the patients with non-small cell lung cancer (NSCLC).
We collected 132 patients pathologically diagnosed as NSCLC from 2010 to 2014. EGFR mutation status in primary tumor or metastatic tumor tissues were detected by PCR amplification refractory mutation system (ARMS). We analyzed the relationship between EGFR mutation status and clinical pathological characteristics and brain metastasis in the patients with disease progression.
Brain metastasis was not correlated with gender or smoking status in NSCLC patients (P > 0.05) but correlated with the age and mutation status of EGFR (P < 0.05). The younger patients with EGFR mutation were more likely to have brain metastases. After EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment, the survival time was significantly prolonged. Smoking was an independent risk factor for the prognosis of the patients with brain metastases.
Patients with EGFR gene mutations are more likely to develop brain metastases. The patients survived longer after receiving TKI therapy and radiotherapy.
| [1] |
Liu J, Zhao R, Zhang J, et al. ARMS for EGFR mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens[J]. J Cancer Res Clin Oncol, 2015, 141(2): 221-7. doi: 10.1007/s00432-014-1807-z
|
| [2] |
李辰星, 吴建中, 王卓, 等.直接测序法和ARMS法检测非小细胞肺癌表皮生长因子受体基因突变的比较[J].中国肺癌杂志, 2014, 17(8): 606-11. http://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201408006.htm
Li CX, Wu JZ, Wang Z, et al. A comparison of direct sequencing and ARMS assay performance in EGFR mutation analysis of non-small cell lung cancer patients[J]. Zhongguo Fei Ai Za Zhi, 2014, 17(8): 606-11. http://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201408006.htm
|
| [3] |
VanderMeer R, Chambers S, Van Dam A, et al. Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care?[J]. Curr Oncol, 2015, 22(4): 272-8. doi: 10.3747/co.22.2526
|
| [4] |
Li M, Zhang Q, Liu L, et al. The different clinical signifi-cance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China[J]. Neoplasma, 2011, 58(1): 74-81. doi: 10.4149/neo_2011_01_74
|
| [5] |
蒋小文, 王文娴, 张沂平.埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析[J].中国肺癌杂志, 2016, 19(4): 200-6. http://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201604005.htm
Jiang XW, Wang WX, Zhang YP. Clinical analysis of icotinib on beneficiary of advanced non-small cell lung cancer with EGFR common mutation[J]. Zhongguo Fei Ai Za Zhi, 2016, 19(4): 200-6. http://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201604005.htm
|
| [6] |
Lu Y, Fan Y. Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis[J]. Onco Targets Ther, 2016, 9: 1135-43.
|
| [7] |
Girard N, Sima CS, Jackman DM, et al. Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma[J]. Eur Respir J, 2012, 39(2): 366-72. doi: 10.1183/09031936.00010111
|
| [8] |
Sekine I, Yamamoto N, Nishio K, et al. Emerging ethnic differences in lung cancer therapy[J]. Br J Cancer, 2008, 99(11): 1757-62. doi: 10.1038/sj.bjc.6604721
|
| [9] |
Mok T, Wu YL, Zhang L. A small step towards personalized medicine for non-small cell lung cancer[J]. Discov Med, 2009, 8(43): 227-31.
|
| [10] |
梁媛, 马锐.非小细胞肺癌EGFR基因突变检测与临床意义[J].医学与哲学, 2014, 35(4B): 70-2. http://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201615085.htm
Liang Y, Ma R. Epidermal growth factor receptor gene mutation and its clinical significance in non-small cell lung cancer[J]. Yi Xue Yu Zhe Xue, 2014, 35(4B): 70-2. http://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201615085.htm
|
| [11] |
Ng DZ, Tan WL, Ong WS, et al. 139PD: Lifetime incidence of brain metastases (BM) in EGFR-mutant (M+) lung cancer treated with first-line EGFR TKIs[J]. J Thorac Oncol, 2016, 11(4 Suppl): S117. https://www.researchgate.net/publication/301333535_139PD_Lifetime_incidence_of_brain_metastases_BM_in_EGFR-mutant_M_lung_cancer_treated_with_first-line_EGFR_TKIs
|
| [12] |
Jiang T, Su C, Li X, et al. EGFR TKIs plus WBRT demonstrated no survival benefit than TKIs alone in NSCLC patients with EGFR mutation and brain metastases[J]. J Thorac Oncol, 2016, 11(10): 1718-28. doi: 10.1016/j.jtho.2016.05.013
|
| [13] |
Kim CH, Lee YC, Hung RJ, et al. Exposure to secondhand tobacco smoke and lung cancer by histological type: a pooled analysis of the International Lung Cancer Consortium (ILCCO)[J]. Int J Cancer, 2014, 135(8): 1918-30. doi: 10.1002/ijc.28835
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: